Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694965 · ClinicalTrials.gov registry record
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 122
- Enrollment target
NCT02694965: Completed study, sponsored by Duke University.
NCT02694965 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02694965 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
Purpose of the study: The investigators are proposing that melanomas which respond and develop eventual disease stability in response to checkpoint inhibitor immunotherapy undergo a genetic program promoting secondary resistance.
Primary Outcome
Arm 1: Differential gene expression will be compared in samples from pre-treatment and disease progression. Arm 2: Differential gene expression will be compared in samples from pre-treatment and disease recurrence.
Interventions
- OTHER observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-01 |
| Est. Completion | 2023-06-07 |
What the finished NCT02694965 record still lists
NCT02694965 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which observational is the first listed.
NCT02694965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02694965 about?
NCT02694965 is a clinical study titled "Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma". Purpose of the study: The investigators are proposing that melanomas which respond and develop eventual disease stability in response to checkpoint inhibitor immunotherapy undergo a genetic program promoting secondary resistance.
What is the current status of trial NCT02694965?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2016-01. Estimated completion is 2023-06-07.
What interventions are being tested in trial NCT02694965?
The interventions under investigation include: observational (OTHER).
Who is sponsoring clinical trial NCT02694965?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia